Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN LOCKSHIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1275523110
CMS profile
239166
Location
SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$363,683.23

523 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 11; records 251–300 of 523 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN LOCKSHIN

NPI 1275523110 · CMS profile ID 239166

Allopathic & Osteopathic Physicians / Dermatology

SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 11; records 251–300 of 523 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275523110?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN LOCKSHIN, NPI 1275523110, CMS profile ID 239166. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 11; records 251–300 of 523 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275523110?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BENJAMIN LOCKSHIN, NPI 1275523110, CMS profile ID 239166. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 11; records 251–300 of 523 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275523110?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BENJAMIN LOCKSHIN, NPI 1275523110, CMS profile ID 239166, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 11; records 251–300 of 523 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1275523110?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

523 matching records · $363,683.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 523 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 523.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ortho Dermatologics, a division of Bausch Health US, LLC $3.2908/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684591791 CMS
Regeneron Healthcare Solutions, Inc. $4,680.0008/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673423077 CMS
AbbVie, Inc. $67.8808/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120813 CMS
AbbVie, Inc. $97.9708/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120815 CMS
Regeneron Healthcare Solutions, Inc. $24.6708/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673423073 CMS
LEO Pharma Inc. $23.7108/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687265827 CMS
Mayne Pharma Inc. $3.7008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705506983 CMS
Lilly USA, LLC $8.0107/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657704757 CMS
Journey Medical Corporation $20.3107/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699280967 CMS
Journey Medical Corporation $20.3107/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699289945 CMS
AbbVie, Inc. $4,900.0007/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120803 CMS
Lilly USA, LLC $10.7507/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657722067 CMS
Regeneron Healthcare Solutions, Inc. $1,040.0007/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673423070 CMS
Janssen Biotech, Inc. $14.3707/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658563267 CMS
AbbVie, Inc. $22.7507/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120563 CMS
AbbVie, Inc. $506.6707/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120807 CMS
AbbVie, Inc. $751.6007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120809 CMS
AbbVie, Inc. $142.7407/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120811 CMS
AbbVie, Inc. $114.9907/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120817 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1.1007/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684591785 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $2.8707/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684591787 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.9207/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684591789 CMS
Encore Dermatology Inc. $18.9407/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698860635 CMS
PFIZER INC. $19.9407/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672315907 CMS
UCB, Inc. $3.1607/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688293787 CMS
Celgene Corporation $20.9807/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672829675 CMS
AbbVie, Inc. $3,500.0007/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120533 CMS
AbbVie, Inc. $116.1306/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120555 CMS
Lilly USA, LLC $2,800.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657711709 CMS
Lilly USA, LLC $2,800.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657715165 CMS
Lilly USA, LLC $1,750.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657718591 CMS
Lilly USA, LLC $2,800.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657722063 CMS
Lilly USA, LLC $2,450.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657725553 CMS
Mayne Pharma Inc. $2.5006/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705506981 CMS
Novartis Pharmaceuticals Corporation $28.7506/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659564531 CMS
AbbVie, Inc. $16.6806/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120551 CMS
Lilly USA, LLC $866.5006/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657704743 CMS
Lilly USA, LLC $311.3506/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657725541 CMS
Lilly USA, LLC $601.0606/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657715157 CMS
Lilly USA, LLC $8.0706/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657718593 CMS
Lilly USA, LLC $11.1206/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657722065 CMS
Galderma Laboratories, L.P. $5.0606/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687698473 CMS
Novartis Pharmaceuticals Corporation $18.0506/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659564533 CMS
Sun Pharmaceutical Industries Inc. $25.6306/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704634521 CMS
AbbVie, Inc. $3,500.0006/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120531 CMS
Celgene Corporation $5.3006/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672813753 CMS
Mayne Pharma Inc. $4.0206/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705506977 CMS
UCB, Inc. $22.0606/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688285427 CMS
AbbVie, Inc. $594.5806/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120535 CMS
AbbVie, Inc. $123.6006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648120537 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $363,683.23 523
PY2020 $238,955.64 276
PY2021 $403,106.46 489
PY2022 $647,846.07 692
PY2023 $818,522.79 788
PY2024 $807,019.31 684
PY2025 $758,149.11 741

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,475.44 8
PY2025 Principal investigator $390,517.34 60
PY2024 Recipient $10,440.71 7
PY2024 Principal investigator $336,307.60 96
PY2023 Recipient $6,500.91 11
PY2023 Principal investigator $394,474.94 131
PY2022 Recipient $11,112.63 26
PY2022 Principal investigator $133,586.13 52
PY2021 Recipient $6,986.32 16
PY2021 Principal investigator $296,972.16 112
PY2020 Recipient $11,700.12 17
PY2020 Principal investigator $399,690.24 151
PY2019 Recipient $36,776.58 17
PY2019 Principal investigator $570,822.87 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $16,482.86 12/31/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228716821
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,000.00 12/26/2025 Non-covered Recipient Entity
Dermassociates
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235997720
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 12/25/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184280318
Principal investigator 1 PFIZER INC. $1,690.88 12/17/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228716823
Principal investigator 1 PFIZER INC. $15,440.00 12/17/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228816598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 12/17/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184276652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,497.00 12/17/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184276654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,518.00 12/17/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184276656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,000.00 12/17/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1184276658
Principal investigator 1 PFIZER INC. $12,778.46 12/03/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228716643
Recipient Regeneron Pharmaceuticals, Inc. $535.71 12/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119767
Principal investigator 1 PFIZER INC. $5,998.06 11/26/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228717599
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,500.00 11/24/2025 Non-covered Recipient Entity
DermAssociates, LLC, dba U.S. Dermatology Partners Rockville
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata No dispute reported 06/30/2026 1252797006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,138.42 11/20/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184263675
Principal investigator 1 PFIZER INC. $2,837.71 11/05/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228716645
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Us Dermatology Partners Rockville
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235992275
Principal investigator 1 PFIZER INC. $2,837.71 10/29/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228823542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 10/23/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184253196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 10/23/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184253198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 10/23/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184253200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 10/23/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184253202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 10/23/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184253204
Principal investigator 1 Incyte Corporation $284.20 10/22/2025 Non-covered Recipient Entity
DERMATOLOGY ASSOCIATES PC
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240526249
Principal investigator 1 PFIZER INC. $1,354.73 10/22/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228823680
Principal investigator 1 ABBVIE INC. $1,032.90 10/09/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514969
Principal investigator 1 PFIZER INC. $1,482.98 09/26/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228833540
Principal investigator 1 PFIZER INC. $10,957.30 09/12/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228833546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 09/04/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 09/04/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184235121
Recipient Regeneron Pharmaceuticals, Inc. $292.99 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119755
Recipient Regeneron Pharmaceuticals, Inc. $60.13 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119757
Recipient Regeneron Pharmaceuticals, Inc. $26.73 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119759
Recipient Regeneron Pharmaceuticals, Inc. $73.50 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119761
Recipient Regeneron Pharmaceuticals, Inc. $2.34 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119763
Recipient Regeneron Pharmaceuticals, Inc. $49.44 08/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119765
Recipient Regeneron Pharmaceuticals, Inc. $434.60 08/27/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184119753
Principal investigator 1 PFIZER INC. $9,244.15 08/23/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228842970
Principal investigator 1 ABBVIE INC. $882.90 08/06/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202502689
Principal investigator 1 PFIZER INC. $4,104.01 08/05/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228842947
Principal investigator 1 PFIZER INC. $4,960.59 07/29/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228845685
Principal investigator 1 Incyte Corporation $1,500.00 07/22/2025 Non-covered Recipient Entity
DERMATOLOGY ASSOCIATES PC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240526254
Principal investigator 1 Incyte Corporation $10,000.00 07/22/2025 Non-covered Recipient Entity
DERMATOLOGY ASSOCIATES PC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240526258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,342.00 07/22/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184217791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,198.00 07/22/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184217793
Principal investigator 1 PFIZER INC. $7,836.35 07/17/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228844977
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,500.00 07/09/2025 Non-covered Recipient Entity
Dermassociates
A Phase III, Randomized, Sponsor Blinded Study of Relatlimab-Nivolumab Fixed Dosed Combination versus Regorafenib or Trifluridine plus Tipiracil for Participants with Later-Lines of Metastatic Colorectal Cancer No dispute reported 06/30/2026 1235997718
Principal investigator 1 ABBVIE INC. $150.00 07/02/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202496353
Principal investigator 1 PFIZER INC. $12,813.14 07/02/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228845690
Principal investigator 1 Eli Lilly and Company $21,669.00 07/01/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187881112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 06/19/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184209418
Principal investigator 1 PFIZER INC. $3,365.56 05/30/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228856943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,425.93 05/27/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184198751
Principal investigator 1 PFIZER INC. $8,252.15 05/16/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228856935
Principal investigator 1 PFIZER INC. $7,168.77 05/06/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228856908
Principal investigator 1 PFIZER INC. $7,995.65 04/09/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228856896
Principal investigator 1 Eli Lilly and Company $1,084.80 03/25/2025 Non-covered Recipient Entity
DERMATOLOGY AND SKIN CANCER SPECIALISTS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187882348
Principal investigator 1 Eli Lilly and Company $24,296.15 03/19/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187880095
Principal investigator 1 PFIZER INC. $5,100.32 03/06/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228861439
Principal investigator 1 PFIZER INC. $10,748.06 03/04/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228861521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 02/20/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 02/20/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 02/20/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155102
Principal investigator 1 Eli Lilly and Company $26,822.00 02/18/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880461
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,657.75 02/12/2025 Non-covered Recipient Entity
Dermassociates
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting No dispute reported 06/30/2026 1235997722
Principal investigator 1 PFIZER INC. $22,014.59 02/11/2025 Non-covered Recipient Entity
DermAssociates
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228833581
Principal investigator 1 Amgen Inc. $1,175.97 01/27/2025 Non-covered Recipient Entity
DERM ASSOCIATES, PC
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246640693
Principal investigator 1 Eli Lilly and Company $48,017.00 01/07/2025 Non-covered Recipient Entity
DERMASSOCIATES PC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187880767
Principal investigator 1 ABBVIE INC. $4,000.00 01/02/2025 Non-covered Recipient Entity
DERMASSOCIATES LLC
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202434918